These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29018366)

  • 1. Editorial: Cardiac Remodeling: New Insights in Physiological and Pathological Adaptations.
    Roever L; Palandri Chagas AC
    Front Physiol; 2017; 8():751. PubMed ID: 29018366
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1-Endothelin-1 Signal Pathway.
    Liu J; Zhuang T; Pi J; Chen X; Zhang Q; Li Y; Wang H; Shen Y; Tomlinson B; Chan P; Yu Z; Cheng Y; Zheng X; Reilly M; Morrisey E; Zhang L; Liu Z; Zhang Y
    Circulation; 2019 Aug; 140(8):665-680. PubMed ID: 31177814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrosis-cell death axis in heart failure.
    Piek A; de Boer RA; Silljé HH
    Heart Fail Rev; 2016 Mar; 21(2):199-211. PubMed ID: 26883434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
    Wu MP; Zhang YS; Xu X; Zhou Q; Li JD; Yan C
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):157-166. PubMed ID: 28321644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms contributing to cardiac remodelling.
    Wu QQ; Xiao Y; Yuan Y; Ma ZG; Liao HH; Liu C; Zhu JX; Yang Z; Deng W; Tang QZ
    Clin Sci (Lond); 2017 Sep; 131(18):2319-2345. PubMed ID: 28842527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury.
    Lacraz GPA; Junker JP; Gladka MM; Molenaar B; Scholman KT; Vigil-Garcia M; Versteeg D; de Ruiter H; Vermunt MW; Creyghton MP; Huibers MMH; de Jonge N; van Oudenaarden A; van Rooij E
    Circulation; 2017 Oct; 136(15):1396-1409. PubMed ID: 28724751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
    Tham YK; Huynh K; Mellett NA; Henstridge DC; Kiriazis H; Ooi JYY; Matsumoto A; Patterson NL; Sadoshima J; Meikle PJ; McMullen JR
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):219-234. PubMed ID: 29217479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.
    Schirone L; Forte M; Palmerio S; Yee D; Nocella C; Angelini F; Pagano F; Schiavon S; Bordin A; Carrizzo A; Vecchione C; Valenti V; Chimenti I; De Falco E; Sciarretta S; Frati G
    Oxid Med Cell Longev; 2017; 2017():3920195. PubMed ID: 28751931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excessive training induces molecular signs of pathologic cardiac hypertrophy.
    da Rocha AL; Teixeira GR; Pinto AP; de Morais GP; Oliveira LDC; de Vicente LG; da Silva LECM; Pauli JR; Cintra DE; Ropelle ER; de Moura LP; Mekary RA; de Freitas EC; da Silva ASR
    J Cell Physiol; 2018 Nov; 233(11):8850-8861. PubMed ID: 29797568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac damage in athlete's heart: When the "supernormal" heart fails!
    Carbone A; D'Andrea A; Riegler L; Scarafile R; Pezzullo E; Martone F; America R; Liccardo B; Galderisi M; Bossone E; Calabrò R
    World J Cardiol; 2017 Jun; 9(6):470-480. PubMed ID: 28706583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of neuropeptides in adverse myocardial remodeling and heart failure.
    Widiapradja A; Chunduri P; Levick SP
    Cell Mol Life Sci; 2017 Jun; 74(11):2019-2038. PubMed ID: 28097372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.
    Valiente-Alandi I; Potter SJ; Salvador AM; Schafer AE; Schips T; Carrillo-Salinas F; Gibson AM; Nieman ML; Perkins C; Sargent MA; Huo J; Lorenz JN; DeFalco T; Molkentin JD; Alcaide P; Blaxall BC
    Circulation; 2018 Sep; 138(12):1236-1252. PubMed ID: 29653926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological and pathological cardiac hypertrophy.
    Shimizu I; Minamino T
    J Mol Cell Cardiol; 2016 Aug; 97():245-62. PubMed ID: 27262674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory Mechanisms of Cardiovascular Remodeling.
    Anzai T
    Circ J; 2018 Feb; 82(3):629-635. PubMed ID: 29415911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice.
    Gao S; Li L; Li L; Ni J; Guo R; Mao J; Fan G
    J Mol Cell Cardiol; 2019 Dec; 137():59-70. PubMed ID: 31629735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Non-cardiomyocyte Cells of the Heart. Their Possible Roles in Exercise-Induced Cardiac Regeneration and Remodeling.
    Varga I; Kyselovič J; Galfiova P; Danisovic L
    Adv Exp Med Biol; 2017; 999():117-136. PubMed ID: 29022261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca
    Suetomi T; Willeford A; Brand CS; Cho Y; Ross RS; Miyamoto S; Brown JH
    Circulation; 2018 Nov; 138(22):2530-2544. PubMed ID: 30571348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte immunoglobulin-like receptor B4 (LILRB4) negatively mediates the pathological cardiac hypertrophy by suppressing fibrosis, inflammation and apoptosis via the activation of NF-κB signaling.
    Li Q; Wei G; Tao T
    Biochem Biophys Res Commun; 2019 Jan; 509(1):16-23. PubMed ID: 30581005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Athlete's heart: frontier between physiology and pathology].
    Rigamonti F; Monnard S; Ziltener JL; Meyer P
    Rev Med Suisse; 2012 Jul; 8(349):1496-500. PubMed ID: 22913000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No overt structural or functional changes associated with PEG-coated gold nanoparticles accumulation with acute exposure in the mouse heart.
    Yang C; Yang H; Wu J; Meng Z; Xing R; Tian A; Tian X; Guo L; Zhang Y; Nie G; Li Z
    Toxicol Lett; 2013 Oct; 222(2):197-203. PubMed ID: 23906719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.